News und Analysen
Fortune Ranks Agilent Among Top Workplaces in Health Care
Agilent Technologies Inc. (NYSE: A) today announced that the company has been named a “Best Workplace in Health Care” in the United States by Fortune magazine. Agilent’s number 17 ranking is based
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with
Agilent Receives Award for Sustainability Leadership
Agilent Technologies Inc. (NYSE: A) has received an award for leadership in advancing environmental sustainability from the Business Intelligence Group. The award recognizes Agilent’s
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for
Simulations Plus to Present at Baird 2022 Global Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and
Premier, Inc.’s Subsidiary Contigo Health, LLC, to Acquire Contracts With 900,000 Providers and Licenses to Cost Containment Technology
Premier, Inc. (NASDAQ: PINC) subsidiary Contigo Health, LLC, a provider of comprehensive services that optimize employee health benefits, today announced an agreement to acquire key assets from
Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of
ICON Releases its 2021 ESG Report
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its 2021 Environmental, Social and Governance (ESG) Report.
The report outlines
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, and Aamir
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, and Aamir
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a live webcast at 2:30 p.m. EDT on Monday, September 26, 2022, with Caroline Roan, Chief Sustainability
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a live webcast at 2:30 p.m. EDT on Monday, September 26, 2022, with Caroline Roan, Chief Sustainability
QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion
DGAP-News: Abivax phase 2b study results of obefazimod (ABX464) in ulcerative colitis published in the Lancet Gastroenterology & Hepatology
Lonza and Touchlight collaborate on end-to-end mRNA offering
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
DGAP-News: Abivax publishes a prospectus in the context of its capital increase
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: ABIVAX: Abivax announces successful oversubscribed EUR 49.2M cross-over financing with top-tier US and European Biotech investors
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor